Skip to main
LEGN

Legend Biotech (LEGN) Stock Forecast & Price Target

Legend Biotech (LEGN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 67%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Legend Biotech is poised for success as they focus on developing innovative CAR-T cell therapies for cancer treatment. Their upcoming presentation at a medical conference and potential label expansions signal growth opportunities for the company. While supply issues for their current product may hinder short-term success, their strong pipeline and potential for future success make Legend Biotech a promising investment opportunity in the biopharmaceutical industry.

Bears say

Legend Biotech is facing several key risks, including production bottlenecks, growing competition in the market, and concentration of risk with reliance on a single product. However, with a healthy balance sheet, potential pipeline updates, and a strong data for their product candidate Carvykti, the company may see potential opportunities for revenue growth and profitability. It will be important to monitor potential risks and updates in the pipeline as well as demand for Carvykti in the market.

Legend Biotech (LEGN) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 67% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Legend Biotech and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Legend Biotech (LEGN) Forecast

Analysts have given Legend Biotech (LEGN) a Buy based on their latest research and market trends.

According to 9 analysts, Legend Biotech (LEGN) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Legend Biotech (LEGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.